Alkylsulfanyl-1,2,4-triazoles, a New Class of Allosteric Valosine Containing Protein Inhibitors. Synthesis and Structure–Activity Relationships

Valosine containing protein (VCP), also known as p97, is a member of AAA ATPase family that is involved in several biological processes and plays a central role in the ubiquitin-mediated degradation of misfolded proteins. VCP is an ubiquitously expressed, highly abundant protein and has been found o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of medicinal chemistry 2013-01, Vol.56 (2), p.437-450
Hauptverfasser: Polucci, Paolo, Magnaghi, Paola, Angiolini, Mauro, Asa, Daniela, Avanzi, Nilla, Badari, Alessandra, Bertrand, Jay, Casale, Elena, Cauteruccio, Silvia, Cirla, Alessandra, Cozzi, Liviana, Galvani, Arturo, Jackson, Peter K, Liu, Yichin, Magnuson, Steven, Malgesini, Beatrice, Nuvoloni, Stefano, Orrenius, Christian, Sirtori, Federico Riccardi, Riceputi, Laura, Rizzi, Simona, Trucchi, Beatrice, O’Brien, Tom, Isacchi, Antonella, Donati, Daniele, D’Alessio, Roberto
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Valosine containing protein (VCP), also known as p97, is a member of AAA ATPase family that is involved in several biological processes and plays a central role in the ubiquitin-mediated degradation of misfolded proteins. VCP is an ubiquitously expressed, highly abundant protein and has been found overexpressed in many tumor types, sometimes associated with poor prognosis. In this respect, VCP has recently received a great deal of attention as a potential new target for cancer therapy. In this paper, the discovery and structure–activity relationships of alkylsulfanyl-1,2,4-triazoles, a new class of potent, allosteric VCP inhibitors, are described. Medicinal chemistry manipulation of compound 1, identified via HTS, led to the discovery of potent and selective inhibitors with submicromolar activity in cells and clear mechanism of action at consistent doses. This represents a first step toward a new class of potential anticancer agents.
ISSN:0022-2623
1520-4804
DOI:10.1021/jm3013213